WO2001004357A2 - Generic sbe-fret protocol - Google Patents
Generic sbe-fret protocol Download PDFInfo
- Publication number
- WO2001004357A2 WO2001004357A2 PCT/US2000/019093 US0019093W WO0104357A2 WO 2001004357 A2 WO2001004357 A2 WO 2001004357A2 US 0019093 W US0019093 W US 0019093W WO 0104357 A2 WO0104357 A2 WO 0104357A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interest
- nucleic acid
- primer
- detection
- acid sequence
- Prior art date
Links
- 238000001514 detection method Methods 0.000 claims abstract description 141
- 239000002773 nucleotide Substances 0.000 claims abstract description 132
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 132
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 125
- 239000000523 sample Substances 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 88
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 87
- 230000000295 complement effect Effects 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000005546 dideoxynucleotide Substances 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 claims description 6
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 claims description 5
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 claims description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 5
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 claims description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 10
- 229940104302 cytosine Drugs 0.000 claims 5
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims 4
- 238000002165 resonance energy transfer Methods 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 abstract description 39
- 238000004458 analytical method Methods 0.000 abstract description 13
- 239000013615 primer Substances 0.000 description 126
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 102000054765 polymorphisms of proteins Human genes 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 14
- 108091093037 Peptide nucleic acid Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000002987 primer (paints) Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000005284 excitation Effects 0.000 description 8
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000003491 array Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 2
- 102100029075 Exonuclease 1 Human genes 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 108010091897 factor V Leiden Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 1
- 108010025544 Bleomycin hydrolase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100437861 Caenorhabditis elegans brc-1 gene Proteins 0.000 description 1
- 101100004654 Caenorhabditis elegans brc-2 gene Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Nucleic acid analysis techniques that identify alterations or polymorphisms within known sequences are useful in many aspects of scientific, medical and forensic fields. For example, these techniques can be used in the genotyping of individuals in order to diagnose hereditary diseases or provide prognosis based on known genetic lesions. These techniques can also be used for clinical purposes such as tissue typing for histocompatibility or for forensic purposes such as identity or paternity determination. Furthermore, nucleic acid analysis techniques can be used for the identification of organisms or to distinguish or identify pathogenic organisms or infectious agents. In addition, these techniques are useful in the identification and monitoring of genetically modified agricultural organisms such as crops and livestock. As genomic sequence of organisms from bacteria to humans become known, the need for nucleic acid analysis techniques that are rapid and inexpensive increases.
- Nucleic acids are readily analyzed and quantitated using probe-based assays.
- the presence of nucleic acid sequences from bacteria, fungi, viruses or other organisms is assayed with nucleic acid probes and such probes are also useful in examining genotypes, genetically-based disease states or other clinical conditions of interest.
- Genotypes of interest include, for example, point mutations, deletions, insertions and inversions.
- these assays are useful to detect and monitor polymorphisms within nucleic acid sequences of interest.
- Probe-based assays typically rely on nucleic acid hybridization.
- Sequence differences of a single base (e.g., point mutation) in very short oligomers can be sufficient to enable the discrimination of the hybridization to complementary nucleic acid target sequences as compared with non-target sequences.
- nucleic acid probes of greater than 10 bp in length are often preferred or required to obtain the sequence specificity necessary to correctly identify a unique organism, disease state or clinical condition of interest.
- hybridization assays large numbers of patient samples can be screened for a large number of loci of interest. Yet, given the requirement that each of the many different probes in the assay exhibit a very high degree of specificity for a specific target nucleic acid sequence under the same or similar conditions of stringency it is often difficult to assay more than one sample and or more than one locus of interest (e.g., multiplex assays).
- An alternative method for identifying and analyzing one or more polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer.
- SBE single-base extension
- FRET fluorescence resonance energy transfer
- the method such as that described by Chen et al, (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific oligonucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest.
- FAM 5-carboxyfluorescein
- the labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxyribonucleotides (ddNTPs) in dye- terminator sequencing fashion, except that no deoxyribonucleotides are present.
- ddNTPs dideoxyribonucleotides
- An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.
- this method requires the use of labeled target-specific oligonucleotide primers for each polymorphism assayed.
- the present invention relates to a method for determining and analyzing polymorphisms which eliminates the need for labeled target-specific primers.
- traditional SBE/FRET protocols are modified in that unlabeled primers are used which comprise a generic or constant sequence on the 5' end of the primer.
- the generic sequence is complementary to a fluorescently- labeled detection probe (e.g., a FAM-labeled detection probe).
- FAM-labeled detection probes can be used for any primer with the generic sequence on the 5' end. This obviates the need for specialized labeled primers and allows for a generic SBE/FRET assay.
- FRET occurs if the detection probe is hybridized to a primer having a nucleotide with a fluorescent acceptor molecule attached thereto (a labeled nucleotide), wherein said labeled nucleotide was added to the primer by template-dependent synthesis, such that it is complementary to the nucleotide of interest or polymorphic nucleotide of interest.
- the present invention retains all of the advantages and uses of standard SBE/FRET, and has the additional advantage of not requiring expensive, target specific primers that are labeled with donor fluorescent molecules. Furthermore, the present invention has the advantage that the detection probe can be reused.
- the present invention is drawn to a method of determining the identity of a nucleotide at a specific location within a nucleic acid sequence of interest.
- the present invention is also drawn to a method for determining the identity of a nucleotide of interest at one or more polymorphic sites in at least one nucleic acid sequence of interest.
- the method comprises forming at least one detection complex comprising a generic detection probe comprising a detection sequence and a donor fluorescent molecule, and an extended primer wherein the primer is extended with a labeled nucleotide by template-dependent synthesis, using the nucleic acid molecule of interest, and more particularly the nucleotide of interest, as the template.
- the primer of the present invention comprises a variable nucleic acid sequence and a nucleic acid sequence (a generic or constant sequence) which hybridizes to (e.g., is complimentary to) said detection sequence.
- the variable portion of said primer hybridizes to a region of the nucleic acid sequence of interest immediately adjacent to a nucleotide of interest and said labeled nucleotide is complementary to said nucleotide of interest.
- the detection complexes formed are detected by fluorescence resonance energy transfer from the donor fluorescent molecule to the acceptor fluorescent molecule.
- the nucleic acid sequence of interest is also part of the detection complex.
- one or more nucleotides of interest in at least one nucleic acid sequence of interest is detected by fluorescence resonance energy transfer from a donor fluorescent molecule on a generic detection probe to an acceptor fluorescent molecule on an extended target-specific primer.
- a donor fluorescent molecule on a generic detection probe to an acceptor fluorescent molecule on an extended target-specific primer.
- acceptor fluorescent molecules when different acceptor fluorescent molecules are used to label the different nucleotides used in the single base extension reaction, the resulting fluorescence resonance energy transfer when a given labeled nucleotide is present in the detection complex with the donor fluorescent molecule, allows differentiation between polymorphic nucleotides at the extended position.
- the present invention is further drawn to a detection probe comprising a detection sequence of about 10 to about 40 nucleotides in length, wherein said probe is labeled with a donor fluorescent molecule.
- the present invention is drawn to a detection probe comprising FAM- GGGCCGGGACCGACCGCGCG (SEQ ID NO: 1).
- the present invention is also drawn to a primer comprising a nucleic acid sequence of about 10 to about 110 nucleotides in length, wherein said primer comprises a variable region and a constant region.
- the constant region comprises CGCGCGGTCGGTCCCGGCCC (SEQ ID NO: 2).
- the present invention is further drawn to a kit for the detection of at least one nucleotide of interest (e.g., at a polymorphic site) in at least one nucleic acid sequence of interest.
- the kit of the present invention comprises at least one detection probe, wherein each detection probe comprises a detection sequence and a donor fluorescent molecule.
- the kit of the present invention can further comprise one or more primers, wherein each primer comprises a variable region and a constant region, such that said variable region hybridizes under appropriate conditions immediately adjacent to a nucleotide of interest in a nucleic acid sequence of interest, and wherein said constant region of said primer hybridizes to a given detection probe (preferably to the detection sequence).
- the kit of the present invention can further comprise dideoxynucleotides labeled with a fluorescent acceptor molecule.
- This invention relates to methods, kits and compositions suitable for the improved detection, quantitation and analysis of nucleic acid target sequences and polymorphisms using single base extension, preferably in conjunction with fluorescence resonance energy transfer.
- the invention is more specifically directed to methods, kits and compositions suitable for specifically detecting, quantitating or identifying one or more target nucleic acids in a sample, or at least one nucleotide of interest (e.g., at a specific site or wherein the nucleotide of interest is a polymorphic nucleotide) within a nucleic acid sequence, even in the presence of non-target sequences.
- the present invention allows the use of generic detection probes in the detection, quantitation and analysis of multiple nucleic acid target sequences, polymorphisms and nucleotides of interest.
- the present invention further allows for the reuse of said detection probes.
- the present invention is particularly well suited for sensitive and reliable SBE/FRET-based assays designed to analyze point mutations.
- the methods, kits and compositions of this invention also find utility for the detection, quantitation or analysis of organisms (micro-organisms), viruses, fungi and genetically-based clinical or forensic conditions of interest.
- Figure 1 is a schematic representation of the method of the present invention.
- Figure 2 A is a scatter plot of the results of G/C polymorphism identification in F13Alu4 (TGTGACAGTTSAGTTTACCAA, SEQ ID NO: 3) using a FAM- labeled FRET primer according to traditional SBE/FRET protocols.
- Figure 2B is a scatter plot of the results of G/C polymorphism identification in F13Alu4 (SEQ ID NO: 3) using the method of the present invention.
- Figure 3 A is a scatter plot of the results of G/C polymorphism identification in PAI2u4 (AGATAACCAASTGCATTTTAT, SEQ ID NO: 4) using a FAM- labeled FRET primer according to traditional SBE/FRET protocols.
- Figure 3B is a scatter plot of the results of G/C polymorphism identification in PAI2u4 (SEQ ID NO: 4) using the method of the present invention.
- Figure 4 A is a scatter plot of the results of G/C polymorphism identification in F5ul8 (AAATAAGGCASATAAGCCCTT, SEQ ID NO: 5) using a FAM-labeled FRET primer according to traditional SBE/FRET protocols.
- Figure 4B is a scatter plot of the results of G/C polymorphism identification in F5ul 8 (SEQ ID NO: 5) using the method of the present invention.
- Figure 5 A is a scatter plot of the results of G/A polymorphism identification in F5u36 (CAACATGCCTRTGGACATGAG, SEQ ID NO: 6) using a FAM- labeled FRET primer according to traditional SBE/FRET protocols.
- Figure 5B is a scatter plot of the results of G/A polymorphism identification in F5u36 (SEQ ID NO: 6) using the method of the present invention.
- This invention relates to methods suitable for the detection, quantitation and analysis of nucleic acid target sequences using fluorescence resonance energy transfer.
- the invention is more specifically directed to methods of forming target- specific detection complexes comprising an extended primer and a detection probe.
- the primer comprises a variable region and a constant region, such that the variable region hybridizes to a target nucleic acid sequence immediately adjacent to a polymorphic nucleotide or nucleotide of interest.
- the primer hybridizes to the target nucleic acid sequence under conditions suitable for the variable portion of the primer to direct template-dependent addition of a single nucleotide labeled with a fluorescent acceptor molecule, thus generating an extended primer.
- the constant region of said primer hybridizes to said detection probe.
- the detection probe is labeled with a donor fluorescent molecule and comprises a detection sequence to which the constant region of the primer hybridizes.
- the detection complex is detected, e.g. by FRET, wherein the sample is interrogated with an appropriate wavelength of light, such that the donor fluorescent molecule is excited, and emitted light is measured at a wavelength suitable to detect emission from the acceptor fluorescent molecule.
- the detection complex comprises an extended primer hybridized to a detection probe.
- the primer is also hybridized to the target nucleic acid sequence (see Figure 1). It is understood that in the alternative, the detection probe can comprise an acceptor fluorescent molecule.
- the single added nucleotide comprises a donor fluorescent molecule.
- the invention is further directed to detection probes and primers for use in said methods and kits containing said detection probes and primers suitable to form said complexes in the presence of a target nucleic acid sequence.
- the detection probes and constant region of said primers comprise guanine/cysteine rich sequence.
- the detection probe and the constant region of said primer comprises SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
- detection probe is defined as any oligomer, comprising nucleic acid subunits, wherein said oligomer is suitable for hybridizing to the constant region of a primer of the present invention.
- Detection probes include ohgomers of peptide nucleic acid, ribonucleic acid, deoxyribonucleic acid, chimeric ohgomers or linked polymers.
- Chimeric ohgomers comprise nucleic acid subunits of more than one type (e.g., DNA with RNA subunits, DNA with PNA subunits, RNA with PNA subunits or all three subunits).
- Linked polymers comprise ohgomers of one type of subunit linked to an oligomer of the same or different subunit. Methods of linking ohgomers comprising DNA, RNA or PNA are well known in the art.
- the preferred length of the detection probe is about 6 to about 50 nucleotides (nucleic acids) in length. More preferably, the detection probe is about 10 to about 25 nucleotides in length. Most preferably, the detection probe is about 20 nucleotides in length.
- "primer" is defined as an oligomer comprising a variable region and a constant region.
- the composition of the primer may be nucleic acid (e.g., ribonucleic acid or deoxyribonucleic acid) or a combination of peptide nucleic acid (PNA) and nucleic acid.
- the target specific region of the primer can be RNA or DNA and the constant region can be nucleic acid, or PNA.
- PNA peptide nucleic acid
- the term "Peptide Nucleic Acid” or "PNA” includes compounds referred to as Peptide Nucleic Acids in United States Patent Nos. 5,539,082, 5,527,675, 5,623,049 or 5,714,331 (the entire teachings of which are incorporated herein by reference). Further modifications of PNA are well known in the art.
- variable region of the primer is the sequence-specific recognition portion of the primer. Therefore, the variable region is a sequence of nucleotides designed to hybridize to a target nucleic acid sequence, if present, under suitable hybridization conditions.
- the length of the variable region will generally be chosen such that a complex is formed between the variable region and the target sequence, wherein the complex is suitable to allow the primer to direct template-dependent synthesis.
- the variable region suitable for the practice of this invention will generally have a length of about 5 and about 60 nucleotides. Preferably, the variable region will be about 10 to about 40 nucleotides. Most preferably, the variable region will be about 15 nucleotides.
- the variable region of the primer will generally have a nucleotide sequence which is complementary to a region of nucleic acid sequence immediately adjacent to the polymorphic nucleotide or nucleotide of interest.
- the constant region of the primer is that portion which hybridizes to the detection probe.
- the constant region of the primer and the detection sequence of the detection probe may be of different lengths, but are preferably the same length.
- the sequence and length of the detection probe and the complementary constant region are chosen to yield a melting temperature (Tm) greater than that of the variable region of the primer.
- Tm melting temperature
- the melting temperature of the constant region is greater than room temperature.
- the Tm of the constant region is greater than about 60°C, allowing the detection complex can be detected at temperatures above 60°C.
- Methods of generating a constant region of suitable Tm are well known in the art (see Ausubel et al, Current Protocols In Molecular Biology, pages 2-10.8 through 2-10.16; Figure 6.4.1, page 8.5.9 and pages 15.521- 15.522, the teachings of which are incorporated herein by reference in their entirety).
- the GC content and/or the length of the constant region can be altered, thereby altering the Tm.
- a detection probe high in GC-content (90%) with a high melting temperature (68°C) is used.
- sequence of a novel FAM-labeled GC-rich detection probe is: FAM-GGGCCGGGACCGACCGCGCG (SEQ ID NO: 1).
- the complementary sequence of the constant region of a primer is: CGCGCGGTCGGTCCCGGCCC (SEQ ID NO: 2), wherein the variable primer sequence is attached to the 3' end of said complementary or constant sequence.
- variable nucleic acid sequence of the primer is selected such that the primer hybridizes immediately adjacent to the polymorphism or nucleotide of interest in the nucleic acid sequence of interest.
- the primer hybridizes such that the polymorphic nucleotide or nucleotide of interest will serve as the first template nucleotide in template directed polymerization from the hybridized primer.
- the length of the variable region of the primer is selected such that it is at least substantially complementary to the target nucleic acid sequence, such that it allows specific hybridization between the primer and the target nucleic acid sequence within the nucleic acid sequence of interest.
- variable portion of the primer may differ in sequence from the complement of the target nucleic acid sequence so long as the target is unambiguously identified and the 3' nucleotide of the primer, which hybridizes adjacent to the polymorphism or nucleotide of interest, is complementary to the corresponding nucleotide in the target nucleic acid sequence, thus allowing the use of the method even when unanticipated polymorphisms or differences exist in the target nucleic acid sequence.
- One of ordinary skill in the art can readily determine, using techniques well known in the art, the necessary length of the variable region to allow specific hybridization to the target nucleic acid sequence.
- substantially complementary means that the variable sequence of the primer need not be the exact complementary sequence of the target nucleic acid sequence, but must be sufficiently similar in identity to the exact complement to hybridize specifically with the target nucleic acid sequence.
- conditions are selected to prevent hybridization of nucleic acid sequences having more than two mismatches out of 20 continuous nucleotides and more preferably more than one mismatch out of 20 continuous nucleotides.
- the variable sequence is exactly complementary to a target nucleic acid sequence.
- polymorphism is an allelic variation in nucleic acid sequence between two or more samples.
- a restriction fragment length polymorphism Is a variation in DNA sequence that alters the length of a restriction fragment (Botstein et ai, Am. J. Hum. Genet. 32, 314-331 (1980)).
- the restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment.
- RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; W090/11369; Donis-Keller, Cell 51, 319-337 (1987); Lander et al, Genetics 121, 85-99 (1989)).
- STRs short tandem repeats
- VNTR variable number tandem repeat
- VNTRs have been used in identity and paternity analysis (US 5,075,217; Armour et ah, FEBSLett. 307, 113-115 (1992); Horn et al, WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.
- polymorphisms take the form of single nucleotide variations between individuals of the same species. Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs.
- Some single nucleotide polymorphisms occur in protein-coding sequences (coding sequence SNP (cSNP)), in which case, one of the polymorphic forms may give rise to the expression of a defective or otherwise variant protein and, potentially, a genetic disease.
- genes in which polymorphisms within coding sequences give rise to genetic disease include ⁇ - globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis).
- cSNPs can alter the codon sequence of the gene and therefore specify an alternative amino acid. Such changes are called “missense” when another amino acid is substituted, and "nonsense" when the alternative codon specifies a stop signal in protein translation. When the cSNP does not alter the amino acid specified the cSNP is called “silent”. Other single nucleotide polymorphisms occur in noncoding regions. Some of these polymorphisms may also result in defective protein expression (e.g., as a result of defective splicing). Other single nucleotide polymorphisms have no phenotypic effects. Single nucleotide polymorphisms can be used in the same manner as
- RFLPs and VNTRs offer several advantages.
- Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism.
- the greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms.
- the different forms of characterized single nucleotide polymorphisms are often easier to distinguish than other types of polymo hism (e.g., by use of assays employing allele-specific hybridization probes or primers as described herein).
- a polymorphic nucleotide is a nucleotide that exhibits a difference between two or more individuals of the same species.
- the method of the present invention detects differences between two or more nucleic acid sequences manifested by at least one nucleotide difference at a specified locus within the sequence.
- a nucleotide of interest refers to a nucleotide at a particular location within a nucleic acid sequence of interest. The location can be specified in relation to the sequence complementary to the variable region of the primer. For example, it is not necessary that the sequence of the nucleic acid sequence of interest be known or that the sequence of the nucleic acid sequence of interest be known on the 3' side of the nucleotide of interest.
- the nucleotide of interest is the nucleotide immediately adjacent to the primer hybridized to the target nucleic acid sequence. In one embodiment, random primers are used.
- one or more target nucleic acid sequence is known and one or more primers are designed to hybridize said target nucleic acid sequence.
- Target nucleic acid sequence refers to that portion of the nucleic acid sequence of interest that hybridizes to the variable region of the primer immediately adjacent to the nucleotide of interest.
- the nucleic acid sequence of interest can be from any number of sources.
- the nucleic acid sequence of interest can be biologically or chemically produced.
- Nucleic acid sequences of interest can be of eubacterial, bacterial, viral or eukaryotic origin.
- Eukaryotic sources include, but are not limited to, fungal, plant, mammalian (e.g., human) and non-mammalian sources.
- the nucleic acid sequence of interest can be of human origin.
- Biological sources of material can be any tissue, biological fluid or extract that contains the nucleic acid sequence of interest.
- the target nucleic acid sequence is specific to a genetically-based disorder or is specific to a predisposition to a genetically-based disorder.
- Suitable disorders can be, for example, ⁇ -Thalassemia, sickle cell anemia or Factor-V Leiden, cystic fibrosis (CF), or cancer-related genes such as p53 and pTEN, or BRC-1 and BRC-2 for breast cancer susceptibility.
- isolated chromosomal DNA may be investigated for paternity testing, identity confirmation or other forensic purpose.
- the nucleic acid sequence of interest can be specific for a pathogen or a microorganism; for example, the nucleic acid sequence of interest can be from a virus, bacterium, fungus, parasite or a yeast. Nucleic acid sequences of interest can be produced as a result of a transcription reaction.
- the nucleic acid sequence of interest can be produced as a result of an amplification reaction; for example, the amplification reaction can be polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription mediated amplification (TMA), Q ⁇ -replicase amplification (Q-beta) or rolling circle amplification (RCA).
- PCR polymerase chain reaction
- LCR ligase chain reaction
- SDA strand displacement amplification
- TMA transcription mediated amplification
- Q-beta Q ⁇ -replicase amplification
- RCA rolling circle amplification
- the nucleic acid sequence of interest can be DNA or RNA.
- PCR products can be detected by the method of the present invention.
- the nucleotide of interest is the nucleic acid amplified in the PCR reaction.
- the variable region of the primer is designed to hybridize the amplified nucleic acid of interest, if present, in the PCR reaction. This method can detect the presence and/or quantity of the nucleic acid of interest.
- the PCR sample can be analyzed in the reaction vessel, or a portion of the PCR reaction can be removed to a separate vessel, or all or a portion of the PCR reaction can be immobilized on a solid support as described below.
- the present invention allows the detection and/or identification of polymorphisms or nucleotides of interest in a single tube or reaction vessel, without washing or removal of non-hybridized probes, primers or unincorporated labeled nucleotides.
- the methods of the present invention also include embodiments that include washing or removal steps. Such washing or removal steps can affect specificity of hybridization due to increased or decreased stringency of said steps.
- washing or removal steps can be useful when the donor and acceptor fluorescent molecules are the same.
- the excitation light is polarized and emission of unpolarized light is indicative of fluorescence resonance energy transfer.
- the SBE can be conducted with one or more primers and one or more nucleic acids of interest, followed by hybridization of the extended primers to detection probes.
- the detection probes may be free in solution or immobilized on a solid support.
- factors commonly used to impose or control stringency of hybridization include formamide concentration (or other chemical denaturant reagent), salt concentration (i.e., ionic strength), hybridization temperature, detergent concentration, pH and the presence or absence of chaotropes.
- Optimal stringency for a probe/target combination is often found by the well known technique of fixing several of the aforementioned stringency factors and then determining the effect of varying a single stringency factor.
- Optimal stringency for an assay may be experimentally determined by examining variations of each stringency factor until the desired degree of discrimination between the variable region and target sequences has been achieved.
- the level of assay stringency will increase or decrease depending on whether the target and variable regions are complementary or substantially complementary.
- Moderate stringency conditions are those that are at least as stringent as 4x SSC at 65°C, or 4x SSC and 50%) formamide at 42°C.
- Reduced stringency conditions are those that are at least as stringent as 4x SSC at 50°C, or 6x SSC and 50% formamide at 40°C.
- variable region of the primer hybridizes to the target nucleic acid sequence immediately adjacent to the polymorphic nucleotide or nucleotide of interest, such that the primer can be used to prime template-dependent synthesis of a nucleic acid molecule, wherein a nucleotide, complementary to a polymorphic nucleotide or nucleotide of interest and labeled with an acceptor fluorescent molecule, is added to the primer.
- template-dependent synthesis is conducted using a thermostable polymerase following a thermocycling protocol.
- thermostable polymerase any suitable thermostable polymerase can be used in the present invention, including, but not limited to, pfu ® , taq ® , Amplitaq ® or Vent ® .
- non-thermostable polymerases can be used, provided conditions are chosen such that sufficient extension occurs. Such conditions include, but are not limited to, augmenting the reaction with additional polymerase, reducing the reaction temperature or performing of a single round of extension. In one embodiment, less than about 30 rounds of thermocycling are performed. In a preferred embodiment, 6 rounds of thermocycling are performed. It is understood that the number of cycles is reduced with increasing specific activity of the detection complex, or with increasing sensitivity of the detection apparatus such that sufficient signal is generated.
- a charge- coupled device can be used to detect FRET, thereby increasing the detection sensitivity.
- the primers and probes can be combined with the nucleic acid sequence of interest simultaneously or sequentially.
- one or more blocking nucleic acid sequences may be used to reduce binding of the primers and probes to non-target sequences.
- Blocking nucleic acid sequences are PNA, RNA or DNA sequences or combinations thereof which are used to suppress the binding of the primer to a site which is unrelated to the target sequence. While not wishing to be bound by theory, it is believed that the blocking sequences suppress the binding of the primer to non- target sequences because the blocking sequences hybridize to the non-target sequence.
- donor and acceptor molecules operate in a set wherein one or more acceptor molecules accepts energy from one or more donor molecules, or otherwise quenches signal from the donor molecule, when the donor and acceptor molecules are closely associated.
- the donor and acceptor molecules are about 30 to about 200 A apart or about 10 to about 40 nucleotides apart.
- Transfer of energy may occur through collision of the closely associated molecules of a set, or through a non-radiative process such as fluorescence resonance energy transfer (FRET).
- FRET fluorescence resonance energy transfer
- transfer of energy between donor and acceptor molecules requires that the molecules be close in space and that the emission spectrum of a donor have substantial overlap with the absorption spectrum of the acceptor (Yaron et al.
- intramolecular energy transfer may occur between very closely associated donor and acceptor molecules (e.g., withm 10 A) whether or not the emission spectrum of a donor molecule has a substantial overlap with the absorption spectrum of the acceptor molecule (Yaron et al) This process is referred to as intramolecular collision since it is believed that quenching is caused by the direct contact of the donor and acceptor molecule (Yaron et al).
- the efficiency of both collision and non-radiative transfer of energy between the donor and acceptor molecules is directly dependent on the proximity of the donor and acceptor molecules
- formation and dissociation of the complexes of this invention can be monitored by measuring at least one physical property of at least one member of the set which is detectably different when the complex is formed, as compared with when the nucleotide primers and probes exist independently and unassociated.
- the means of detection will involve measuring fluorescence of an acceptor fluorophore of a set or the fluorescence of the donor fluorophore in a set containing a fluorophore and quencher pair (e.g. a donor and acceptor).
- the fluorescent molecules may interact with one another via hydrophobic interactions, thereby reducing the adverse effect of distance between the donor and acceptor fluorescent molecules.
- fluorescence energy transfer can occur when the donor and acceptor fluorescent molecules are up to about 40 nucleotides away from each other.
- the detection complex comprising the primer extend by an acceptor- labeled nucleotide and the detection probe is no longer hybridized to the target nucleic acid sequence when acceptor molecule fluorescence is measured.
- the acceptor molecule fluorescence is measured at a temperature above the Tm of the variable region.
- the ddNTP corresponding to the complement of one possible nucleotide present at the polymorphic locus is labeled with N, N,, N, N 1 - tetramethyl-6-carboxy rhodamine (TAMRA) and the complement of another possible nucleotide present at the polymorphic locus is labeled with 6- carboxy-X-rhodamine (ROX), (see Example 2).
- TAMRA 6- carboxy-X-rhodamine
- the FRET primer is extended with a ROX- labeled or TAMRA-labeled ddNTP.
- the donor fluorescent molecule Upon incorporation of either ROX- or TAMRA-labeled ddNTP, energy transfer occurs between the donor dye (FAM) of the detector probe and the acceptor dye (the ROX- or TAMRA- attached to the ddNTP).
- Donor and acceptor molecules suitable for FRET are well known in the art (see page 46 of R.P. Haugland, Handbook of Fluorescent Probes and Research Chemicals 6th ed.; Molecular Probes, Oregon, the teachings of which are incorporated herein by reference).
- the donor fluorescent molecule has a shorter excitation wavelength than the acceptor fluorescent molecule and the donor emission wavelength overlaps with the acceptor excitation wavelength, to allow transfer of energy from the donor to the acceptor.
- Preferred fluorophores are fluorescein and derivatives thereof, such as 5-(2'- aminoethyl)-aminoapthalene-l-sulfonic acid (EDANS) and rhodamine and derivatives thereof such as Cy3, Cy5 and Texas Red.
- EDANS 5-(2'- aminoethyl)-aminoapthalene-l-sulfonic acid
- rhodamine and derivatives thereof such as Cy3, Cy5 and Texas Red.
- Suitable donor/acceptor pairs are, for example, fluorescein/tetramethyrhodamine, IAEDANS/fluorescein and EDANS/DABCYL.
- the same fluorescent molecule is used for the donor and acceptor.
- the wavelength used to excite the detection complexes is polarized. Unpolarized emission detected is indicative of FRET.
- labeled, unlabeled and modified nucleotides are readily available for the method of the present invention. They can be synthesized using commercially available instrumentation and reagents or they can be purchased from numerous commercial vendors of custom manufactured oligonucleotides.
- the method of the present invention can be used to analyze more than one polymorphic nucleotide or nucleotide of interest in a given nucleic acid sequence of interest. Furthermore, the present invention can be used to analyze multiple nucleic acid sequences for one or more polymorphic nucleotides or nucleotides of interest. These embodiments are referred to herein as multiplex analysis. For example, a single polynucleic acid of interest can be analyzed at two or more loci. In this example, primers are used such that the variable region of each primer is distinct and hybridizes to unique target nucleic acid sequence (specific locus of interest).
- each primer can have a unique constant region, such that a detection probe specific for each primer and labeled with a distinguishable donor fluorescent molecule is used.
- the nucleotide of interest at each locus is analyzed by interrogation at different excitation wavelengths, wherein each wavelength is specific for a donor molecule. Detection is measured at the acceptor emission wavelength.
- the same set of acceptor labeled nucleotides can be used for each locus.
- the same detector fluorescent molecule can be used for each locus.
- a positive read-out is obtained when either locus is detected in the sequence of interest.
- the set of donor and acceptor molecules can be chosen such that a unique read-out is obtained for each locus, wherein the readout is defined by the excitation and emission wavelength.
- the present invention further provides a method to diagnose a genetically- based disorder or predisposition for a genetically-based disorder, wherein two or more nucleotides of interest are related to each other and wherein, detection of any one of said nucleotides is useful or necessary to the proper diagnosis.
- the nucleotides of interest can have similar sequence.
- the present invention can be used to detect any number of mutations in the -globin gene cluster or in the ⁇ -globin gene cluster, where any one of said mutations results in Thalassemia.
- the nucleotide sequences of interest do not share sequence similarity, yet presence of any one of the sequences can be used to diagnose disease or predisposition to disease.
- genes linked to a predisposition in Alzheimer's disease such as ApoE, bleomycin hydrolase or ⁇ - amyloid precursor protein can be analyzed for alterations associated with Alzeheimer's disease.
- at least two probe sets are used, such that the variable region of the first and second primers of each set are distinct. Said probe sets hybridize to unique target nucleic acid sites.
- the FRET readout or acceptor molecule emission of all complexes can be the same regardless of the nature of the unique target nucleic acid sequence to which they are bound.
- the presence of any one of a group of target nucleic acid sequence in a sample will result in the generation of a positive signal.
- the same detection probe can be used. Examples of such diseases and conditions of clinical interest have been previously described.
- the present invention can be used to analyze one or more polymorphic nucleotides, one or more nucleotides of interest and combinations thereof.
- the different polymorphisms or nucleotides of interest analyzed in the single reaction are distinguishable.
- different sets of donor and acceptor fluorescent molecules are used to distinguish the different nucleotides of interest.
- detection probes can comprise donor fluorescent molecules of different excitation wavelengths and distinct detection sequences.
- one target-specific primer has a constant region that hybridizes to one detector probe, and a primer specific for another target sequence has a constant region complementary to a second detector probe.
- the same acceptor molecule labeled nucleotides can be used, and detection is conducted at separate excitation wavelengths. It is understood that any combination of donor and acceptor molecules with different detection sequences can be used to distinguish the nucleotides of interest on one or more polynucleic acid of interest.
- either the detector probes, primers or polynucleic acids of interest can be immobilized onto a solid support.
- the different detector probes can be immobilized on a solid support at defined locations.
- primers having a constant region that is complementary to an immobilized detection probe are used.
- multiple primers can be used in solution with polynucleic acid of interest followed by hybridization of the extended primers to the immobilized detection probes.
- the primers can be hybridized to the detection probes before SBE.
- Multiple nucleotides of interest can be analyzed simultaneously in the same tube or vessel, where "vessel" includes any suitable solid support such as wells, slides, chips or beads.
- Each nucleotide of interest is distinguished by its location on the solid support as well as the FRET readout, thus, the same detector/acceptor pairs can be used for each nucleotide of interest.
- the immobilized detection probe can optionally be reused after removal of hybridized primer or hybridized primer/target nucleic acid sequence complex.
- the primers are immobilized on a solid support.
- primers having variable regions complementary to different target nucleic acid sequences are used.
- the detection probe can be added before or after SBE. Multiple nucleotides of interest can be analyzed simultaneously in the same tube or vessel. If more than one target site is being analyzed, the primers can be mutually distinguishable.
- the primers are immobilized at known locations. In another embodiment, the primers have distinguishable constant regions.
- nucleic acid sequences of interest comprising various target sites are immobilized on a solid support at defined locations.
- a given immobilized nucleic acid sequence of interest can be analyzed for more than one polymorphism or nucleotide of interest at more than one target site within the nucleic acid of interest.
- the detection probe and acceptor molecule pairs can be selected to detect each of the polymorphic nucleotides or nucleotides of interest separately, or to detect any one of the polymorphic nucleotides or nucleotides of interest.
- arrays are surfaces on which two or more detection complexes have been formed, each detection complex at a specified position. Because the location and composition of each detection complex is known, arrays are generally used to simultaneously detect, identify or quantitate two or more target nucleic acid sequences in the sample. Thus, arrays of detection complexes may be useful in diagnostic applications or in screening compounds.
- an array of unique support-bound detection probes or primers could be manufactured, wherein each support-bound detection probe or primer exists at a known location on the array.
- Each support-bound detection probe or primer would be suitable for the detection or quantitation of one of several unique target nucleic acid sequences which might be present in a sample.
- the sample of interest is contacted with the support in the presence of a mixture of primer or detection probes and acceptor-labeled nucleotides, under conditions suitable for the formation of detection complexes at a position on the array.
- the primers are immobilized and suitable detection probes are added.
- detection probes are immobilized and suitable primers are added. Suitable probes, for example have detection sequences complimentary to the constant region of the primer.
- Suitable primers for example have a constant region complimentary to the immobilized detection probe and a variable region complimentary to the target nucleic acid sequence.
- the presence or identity of at least one target nucleic acid sequence can be correlated with the presence of detectable FRET signal at a defined location on the array.
- a common detection probe is used.
- the same detection probe can be used to generate signal at any position on the array where a primer has been extended.
- the present invention further comprises primer/probe sets comprising a target-specific primer and a detection probe, wherein said primer comprises a variable region and a constant region, such that the variable region is complementary to a target nucleic acid sequence immediately adjacent to the polymorphic nucleotide or target nucleotide of interest and wherein the constant region is complementary to the detection sequence of the detection probe, wherein the detection probe is labeled with a donor fluorescent molecule.
- the detection sequence comprises a G/C rich sequence.
- the detection sequence comprises SEQ ID NO: 1.
- the constant region of said primer comprises SEQ ID NO: 2.
- kits suitable for detection of polymo ⁇ hisms or nucleotides of interest comprise kits suitable for detection of polymo ⁇ hisms or nucleotides of interest.
- the kits of the present invention comprise at least one detection probe comprising a detection sequence, wherein said detection probe is labeled with a donor fluorescent molecule.
- the kit can further comprise a primer, wherein said primer comprises a variable region and a constant region, such that the variable region hybridizes under appropriate conditions immediately adjacent to a polymo ⁇ hism a nucleic acid sequence of interest.
- the constant region of the primer hybridizes to said detection probe.
- the kit can further comprise dideoxynucleotides labeled with fluorescent acceptor molecules.
- the locus of interest was amplified using polymerase chain reaction.
- a PCR mix was prepared following the recipe below:
- a SBE-FRET mix was prepared following the recipe below:
- TAMRA base SBE-PRIMER (20 ⁇ M) 2.0 208
- Figure 2 shows the results of analysis of a polymo ⁇ hic site in locus F13Alu4 (SEQ ID NO: 3) wherein the nucleotide of interest is G or C.
- Figure 2a shows the results from conventional SBE/FRET where the target specific primer is labeled with both the donor and acceptor molecules.
- Figure 2b shows the results from the method of the present invention, using a generic detection probe.
- Figures 3-5 show similar analyses at different loci, in particular at PAI2U4, F5U18 and F5U36, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60950/00A AU6095000A (en) | 1999-07-13 | 2000-07-13 | Generic sbe-fret protocol |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14359899P | 1999-07-13 | 1999-07-13 | |
US60/143,598 | 1999-07-13 | ||
US16197599P | 1999-10-28 | 1999-10-28 | |
US60/161,975 | 1999-10-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001004357A2 true WO2001004357A2 (en) | 2001-01-18 |
WO2001004357A3 WO2001004357A3 (en) | 2001-07-26 |
WO2001004357A9 WO2001004357A9 (en) | 2002-07-25 |
Family
ID=26841215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/019093 WO2001004357A2 (en) | 1999-07-13 | 2000-07-13 | Generic sbe-fret protocol |
Country Status (3)
Country | Link |
---|---|
US (1) | US6642001B1 (en) |
AU (1) | AU6095000A (en) |
WO (1) | WO2001004357A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002099127A1 (en) * | 2001-06-06 | 2002-12-12 | Biohit Oyj | Method for determining the presence of extension products |
EP1379692A1 (en) * | 2001-03-30 | 2004-01-14 | Applera Corporation | Nucleic acid analysis using non-templated nucleotide addition |
EP2366798A1 (en) * | 2002-03-12 | 2011-09-21 | Enzo Life Sciences, Inc. | Nucleic acid detection process involving energy transfer labels on nucleotide |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875440B2 (en) | 1998-05-01 | 2011-01-25 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US6780591B2 (en) | 1998-05-01 | 2004-08-24 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
DE10132211A1 (en) * | 2001-06-27 | 2003-01-16 | Epigenomics Ag | Detection of specific dinucleotides in DNA samples by fluorescence resonance energy transfer (FRET) |
JP2003084002A (en) * | 2001-06-27 | 2003-03-19 | Fuji Photo Film Co Ltd | Method for reducing background in fluorescence detection |
US9353405B2 (en) | 2002-03-12 | 2016-05-31 | Enzo Life Sciences, Inc. | Optimized real time nucleic acid detection processes |
US20040191776A1 (en) * | 2003-03-21 | 2004-09-30 | Pei-Jer Chen | Method for genotyping and quantifying Hepatitis B Virus |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
WO2005056838A1 (en) * | 2003-12-08 | 2005-06-23 | The Clinic For Special Children | Association of tspyl polymorphisms with siddt syndrome |
US7981604B2 (en) | 2004-02-19 | 2011-07-19 | California Institute Of Technology | Methods and kits for analyzing polynucleotide sequences |
US20080317964A1 (en) * | 2005-02-10 | 2008-12-25 | Rocco Vincent Burgo | High Temperature Lubricant Compositions and Methods of Making the Same |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
US7876894B2 (en) * | 2006-11-14 | 2011-01-25 | Mcm Portfolio Llc | Method and system to provide security implementation for storage devices |
US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
US20110098309A1 (en) * | 2007-07-12 | 2011-04-28 | Acumen Pharmaceuticals, Inc. | Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
US8569254B2 (en) | 2010-12-10 | 2013-10-29 | National Yang Ming University | Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same |
US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124221A1 (en) * | 1983-03-09 | 1984-11-07 | Alan David Blair Malcolm | Method of detecting a polynucleotide sequence and labelled polynucleotides useful therein |
EP0229943B1 (en) * | 1985-12-23 | 1991-09-04 | Molecular Biosystems, Inc. | Fluorescent stokes shift probes for polynucleotide hybridization assays |
WO1992014845A1 (en) * | 1991-02-26 | 1992-09-03 | Worcester Foundation For Experimental Biology | Diagnosing cystic fibrosis and other genetic diseases using fluorescence resonance energy transfer (fret) |
WO1993025563A1 (en) * | 1992-06-17 | 1993-12-23 | City Of Hope | A method of detecting and discriminating between nucleic acid sequences |
WO1997022719A1 (en) * | 1995-12-18 | 1997-06-26 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
WO1997031256A2 (en) * | 1996-02-09 | 1997-08-28 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
GB2312747A (en) * | 1996-05-04 | 1997-11-05 | Zeneca Ltd | Primers with non-complementary tails for detection of diagnostic base sequences |
US5710028A (en) * | 1992-07-02 | 1998-01-20 | Eyal; Nurit | Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4996143A (en) | 1985-12-23 | 1991-02-26 | Syngene, Inc. | Fluorescent stokes shift probes for polynucleotide hybridization |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US5888819A (en) | 1991-03-05 | 1999-03-30 | Molecular Tool, Inc. | Method for determining nucleotide identity through primer extension |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
US5650277A (en) | 1992-07-02 | 1997-07-22 | Diagenetics Ltd. | Method of determining the presence and quantifying the number of di- and trinucleotide repeats |
GB9609441D0 (en) * | 1996-05-04 | 1996-07-10 | Zeneca Ltd | Process |
US5888778A (en) * | 1997-06-16 | 1999-03-30 | Exact Laboratories, Inc. | High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers |
US5916776A (en) | 1997-08-27 | 1999-06-29 | Sarnoff Corporation | Amplification method for a polynucleotide |
US6322968B1 (en) | 1997-11-21 | 2001-11-27 | Orchid Biosciences, Inc. | De novo or “universal” sequencing array |
-
2000
- 2000-07-13 US US09/615,216 patent/US6642001B1/en not_active Expired - Lifetime
- 2000-07-13 WO PCT/US2000/019093 patent/WO2001004357A2/en active Application Filing
- 2000-07-13 AU AU60950/00A patent/AU6095000A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124221A1 (en) * | 1983-03-09 | 1984-11-07 | Alan David Blair Malcolm | Method of detecting a polynucleotide sequence and labelled polynucleotides useful therein |
EP0229943B1 (en) * | 1985-12-23 | 1991-09-04 | Molecular Biosystems, Inc. | Fluorescent stokes shift probes for polynucleotide hybridization assays |
WO1992014845A1 (en) * | 1991-02-26 | 1992-09-03 | Worcester Foundation For Experimental Biology | Diagnosing cystic fibrosis and other genetic diseases using fluorescence resonance energy transfer (fret) |
WO1993025563A1 (en) * | 1992-06-17 | 1993-12-23 | City Of Hope | A method of detecting and discriminating between nucleic acid sequences |
US5710028A (en) * | 1992-07-02 | 1998-01-20 | Eyal; Nurit | Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor |
WO1997022719A1 (en) * | 1995-12-18 | 1997-06-26 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
WO1997031256A2 (en) * | 1996-02-09 | 1997-08-28 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
GB2312747A (en) * | 1996-05-04 | 1997-11-05 | Zeneca Ltd | Primers with non-complementary tails for detection of diagnostic base sequences |
Non-Patent Citations (3)
Title |
---|
BOLK S ET AL: "High-throughput SNP genotyping using single-base extension." AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10), page A97 XP000979094 49th Annual Meeting of the American Society of Human Genetics;San Francisco, California, USA; October 19-23, 1999 ISSN: 0002-9297 * |
CHEN ET AL: "FLUORESCENCE ENERGY TRANSFER DETECTION AS A HOMOGENEOUS DNA DIAGNOSTIC METHOD" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 94, 1997, pages 10756-10761, XP002141333 ISSN: 0027-8424 * |
PASTINEN T ET AL: "MINISEQUENCING: A SPECIFIC TOOL FOR DNA ANALYSIS AND DIAGNOSTICS ONOLIGONUCLEOTIDE ARRAYS" GENOME RESEARCH,US,COLD SPRING HARBOR LABORATORY PRESS, vol. 7, no. 6, 1 June 1997 (1997-06-01), pages 606-614, XP000699761 ISSN: 1088-9051 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1379692A1 (en) * | 2001-03-30 | 2004-01-14 | Applera Corporation | Nucleic acid analysis using non-templated nucleotide addition |
EP1379692A4 (en) * | 2001-03-30 | 2005-08-31 | Applera Corp | Nucleic acid analysis using non-templated nucleotide addition |
WO2002099127A1 (en) * | 2001-06-06 | 2002-12-12 | Biohit Oyj | Method for determining the presence of extension products |
EP2366798A1 (en) * | 2002-03-12 | 2011-09-21 | Enzo Life Sciences, Inc. | Nucleic acid detection process involving energy transfer labels on nucleotide |
Also Published As
Publication number | Publication date |
---|---|
WO2001004357A3 (en) | 2001-07-26 |
WO2001004357A9 (en) | 2002-07-25 |
AU6095000A (en) | 2001-01-30 |
US6642001B1 (en) | 2003-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6642001B1 (en) | Generic SBE-FRET protocol | |
JP5385973B2 (en) | Simultaneous detection of multiple nucleic acid sequences in a reaction | |
US6287781B1 (en) | Method for detection of target nucleic acids using PCR | |
US7090975B2 (en) | Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection | |
US6579680B2 (en) | Method for label-free detection of hybridized DNA targets | |
US5780233A (en) | Artificial mismatch hybridization | |
US8852863B2 (en) | Detection of multiple nucleic acid sequences in a reaction cartridge | |
AU1821097A (en) | Method for nucleic acid analysis using fluorescence resonance energy transfer | |
JP2004506431A (en) | Single-label oligonucleotide probe | |
WO1992016657A1 (en) | Method of identifying a nucleotide present at a defined position in a nucleic acid | |
CA2470356A1 (en) | Analysis and detection of multiple target sequences using circular probes | |
EP1829964A1 (en) | Method of examining gene sequence | |
AU2473900A (en) | Primer extension methods utilizing donor and acceptor molecules for detecting nucleic acids | |
US20040009514A1 (en) | Assembly for label-free detection of hybridized nucleic targets | |
AU2003247603A1 (en) | Methods and compositions for monitoring primer extension and polymorphism detection reactions | |
US20030077584A1 (en) | Methods and compositons for bi-directional polymorphism detection | |
CA2705852C (en) | Photoinduced electron transfer (pet) primer for nucleic acid amplification | |
WO2002034937A9 (en) | Methods for detection of differences in nucleic acids | |
US6440675B1 (en) | Methods for selecting primers | |
WO2005003373A2 (en) | Fluorogenic nucleic acid probes including lna for methods to detect and/or quantify nucleic acid analytes | |
JP4310675B2 (en) | Nucleotide polymorphism identification method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |